INZY Share Price | Inozyme Pharma, Inc. Stock Analysis & Recommendation

Q: What does Inozyme Pharma, Inc. do?

Overview: Inozyme Pharma, Inc. is a rare disease biopharmaceutical company focused on developing therapeutics for diseases of abnormal mineralization, specifically targeting ENPP1 and ABCC6 deficiencies within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Profit: -28 Million (Quarterly Results - Mar 2025) Market cap: USD 257.28 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.20 Return on Equity: -329.63% Price to Book: 8.09Contact Details: Address: 321 SUMMER STREET, SUITE 400, BOSTON MA : 02210 Tel: 1 857 3304340 Fax: 1 302 6555049 Website: http://www.inozyme.com/

Q: Is Inozyme Pharma, Inc. technically bullish or bearish?

As of 30 June 2025, the technical trend for Inozyme Pharma, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the weekly RSI indicates bearish momentum, and both the KST and Dow Theory show mixed signals with bearish readings on the monthly. In terms of performance, the stock has returned 44.4% year-to-date, significantly outperforming the S&P 500's 12.22% return, but it has underperformed over the 1-year and 3-year periods.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Mar 2025)

FII

4.82%

Held by 37 FIIs

DII

54.04%

Held by 24 DIIs

Promoter

23.47%

How big is Inozyme Pharma, Inc.?

22-Jun-2025

As of Jun 18, Inozyme Pharma, Inc. has a market capitalization of 257.28 million and reported net sales of 0.00 million with a net profit of -106.71 million over the last four quarters. Shareholder's funds were 57.83 million, and total assets were 123.18 million.

View full answer

What does Inozyme Pharma, Inc. do?

22-Jun-2025

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases related to abnormal mineralization, specifically targeting ENPP1 and ABCC6 deficiencies. As of March 2025, it has a market cap of $257.28 million and reported a net profit loss of $28 million.

View full answer

Who are in the management team of Inozyme Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of Inozyme Pharma, Inc. includes Dr. Douglas Treco (Independent Chairman), Mr. Axel Bolte (President and CEO), and several Independent Directors: Ms. Sarah Bhagat, Mr. Reinaldo Diaz, Dr. Martin Edwards, and Dr. Robert Hopfner.

View full answer

Is Inozyme Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of June 30, 2025, Inozyme Pharma, Inc. shows a mildly bullish trend with a 44.4% year-to-date return, despite mixed technical signals and underperformance over the past year and three years.

View full answer

Compare Inozyme Pharma, Inc. with Similar Stocks

Compass Therapeutics, Inc.Lexicon Pharmaceuticals, Inc.Atea Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 257 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

96.09%

Debt Equity

-1.20

Return on Equity

-329.63%

Price to Book

8.08

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

-28 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

277.36%

6 Months

34.23%

1 Year

-16.14%

2 Years

-34.43%

3 Years

-8.68%

4 Years

-78.01%

5 Years

0.0%

Inozyme Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-29.63%

EBIT to Interest (avg)

-40.92

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.20

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

92.82%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

8.10

EV to EBIT

-2.08

EV to EBITDA

-2.10

EV to Capital Employed

-34.64

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-329.63%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 31 Schemes (17.67%)

Foreign Institutions

Held by 37 Foreign Institutions (4.82%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -20.17% vs -33.91% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.60",
          "val2": "-24.20",
          "chgp": "-5.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "1.30",
          "chgp": "7.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-28.00",
          "val2": "-23.30",
          "chgp": "-20.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -43.26% vs -6.11% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-102.80",
          "val2": "-74.40",
          "chgp": "-38.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.60",
          "val2": "3.30",
          "chgp": "69.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-102.00",
          "val2": "-71.20",
          "chgp": "-43.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-25.60

-24.20

-5.79%

Interest

1.40

1.30

7.69%

Exceptional Items

-1.90

0.00

Consolidate Net Profit

-28.00

-23.30

-20.17%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -20.17% vs -33.91% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-102.80

-74.40

-38.17%

Interest

5.60

3.30

69.70%

Exceptional Items

0.00

Consolidate Net Profit

-102.00

-71.20

-43.26%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -43.26% vs -6.11% in Dec 2023

All Annual Results

Company CV

About Inozyme Pharma, Inc.

Inozyme Pharma, Inc.

Pharmaceuticals & Biotechnology

Inozyme Pharma, Inc. is a rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

Company Coordinates

Company Details

321 SUMMER STREET, SUITE 400 , BOSTON MA : 02210

Tel: 1 857 3304340

http://www.inozyme.com/

Registrar Details

Inozyme Pharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Inozyme Pharma, Inc.?

Watch in Real-Time

What does Inozyme Pharma, Inc. do?

Who are in the management team of Inozyme Pharma, Inc.?

Is Inozyme Pharma, Inc. technically bullish or bearish?

Compare Inozyme Pharma, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Inozyme Pharma, Inc.

Company Coordinates